ReviewPediatric cardiology2025
Systemic-Pulmonary Collaterals in KCNT1-Related Disorders: Precise Nomenclature and Management.
Review in Pediatric cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic variants in KCNT1, a gene encoding a sodium-activated potassium channel, are classically associated with severe early-onset epileptic encephalopathies. Emerging evidence indicates that some individuals with KCNT1-related disorders also develop systemic-to-pulmonary vascular anomalies, often initially misidentified as major aortopulmonary collateral arteries (MAPCAs) due to radiographic similarities with congenital heart disease. Unlike true MAPCAs, these vessels arise in the absence of structural cardiac defects and appear to result from abnormal angiogenesis driven by dysregulated KCNT1-mediated signaling. Misclassification may lead to inappropriate interventions or management strategies. Here, a multidisciplinary expert working group reviewed published cases, institutional experience, and imaging findings to develop an expert opinion for nomenclature, diagnosis, and management of these vascular anomalies. We recommend adopting the term systemic-pulmonary collaterals (SPCs) to accurately describe these angiogenic vessels. Risk-based screening, judicious catheter-based embolization when physiologically indicated, and careful avoidance of standard pulmonary vasodilators are emphasized. This statement aims to improve clinical recognition, precision in terminology, and safe management of vascular complications in patients with KCNT1-related disorders.
Indexed as
Identifiers
41389134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.